Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Status:
Completed
Trial end date:
2021-06-07
Target enrollment:
Participant gender:
Summary
Hospitalized patients with histologically or cytologically confirmed diagnosis of solid tumor
malignancy, lymphoma, or multiple myeloma and who are at high risk for a venous
thromboembolism will be randomized to standard dose versus intermediate dose enoxaparin.